Skip to main content

Table 3 Univariate and multivariate analysis with the OS, DSS, LRRFS and DMFS for the poor-prognosis group among elderly NPC patients

From: Selection and validation of chemotherapy beneficiaries among elderly nasopharyngeal carcinoma (NPC) patients treated with intensity-modulated radiation therapy (IMRT): a large real-world study

Characteristic

OS

DSS

DMFS

LRRFS

HR (95% CI)

*P

HR (95% CI)

*P

HR (95% CI)

*P

HR (95% CI)

*P

Univariate analysis

Gender

 Male

Reference

 

Reference

 

Reference

 

Reference

 

 Female

0.677 (0.524, 0.874)

0.003

0.762 (0.565, 1.028)

0.075

0.699 (0.487, 1.002)

0.052

0.750 (0.489, 1.150)

0.187

Age at diagnosis, years

 60–64

Reference

 

Reference

 

Reference

 

Reference

 

 65–69

1.453 (1.163, 1.815)

0.001

1.176 (0.899, 1.538)

0.238

1.188 (0.868, 1.625)

0.282

0.972 (0.658, 1.437)

0.887

  ≥ 70

1.781 (1.385, 2.290)

 < 0.001

1.312 (0.953, 1.806)

0.096

1.214 (0.826, 1.786)

0.324

1.134 (0.711, 1.809)

0.597

Histological type

 WHO type I–II

Reference

 

Reference

 

Reference

 

Reference

 

 WHO type III

0.75 (0.422, 1.334)

0.328

0.659 (0.339, 1.282)

0.219

0.578 (0.272, 1.230)

0.155

1.107 (0.352, 3.481)

0.862

ACE-27(scores)

 0

Reference

 

Reference

 

Reference

 

Reference

 

 1

0.931 (0.757, 1.144)

0.494

0.868 (0.674, 1.119)

0.276

0.953 (0.705, 1.287)

0.753

0.648 (0.447, 0.937)

0.021

 2

1.885 (1.359, 2.615)

 < 0.001

1.947 (1.331, 2.849)

0.001

2.117 (1.380, 3.247)

0.001

1.579 (0.907, 2.749)

0.106

Family history of cancer

 No

Reference

 

Reference

 

Reference

 

Reference

 

 Yes

0.911 (0.730, 1.138)

0.412

0.87 (0.662, 1.144)

0.319

0.859 (0.621, 1.189)

0.359

1.105 (0.764, 1.598)

0.596

Smoking

 No

Reference

 

Reference

 

Reference

 

Reference

 

 Yes

1.278 (1.053, 1.552)

0.013

1.225 (0.967, 1.551)

0.092

1.319 (0.998, 1.742)

0.051

1.039 (0.740, 1.458)

0.825

Alcohol consumption

 No

Reference

 

Reference

 

Reference

 

Reference

 

 Yes

1.000 (0.770, 1.297)

0.997

0.907 (0.652, 1.261)

0.560

1.062 (0.731, 1.544)

0.751

0.811 (0.494, 1.332)

0.408

Chemotherapy

 No

Reference

 

Reference

 

Reference

 

Reference

 

 Yes

0.697 (0.549, 0.883)

0.003

0.826 (0.613, 1.114)

0.210

0.863 (0.608, 1.226)

0.411

0.975 (0.623, 1.527)

0.913

Multivariate analysis

Gender

 Male

Reference

 

Reference

 

Reference

 

Reference

 

 Female

0.777 (0.587, 1.028)

0.077

0.848 (0.61, 1.18)

0.328

0.792 (0.533, 1.177)

0.249

0.754 (0.474, 1.201)

0.235

Age at diagnosis, years

 60–64

Reference

 

Reference

 

Reference

 

Reference

 

 65–69

1.457 (1.162, 1.828)

0.001

1.206 (0.917, 1.585)

0.180

1.231 (0.895, 1.694)

0.202

1.009 (0.678, 1.502)

0.965

  ≥ 70

1.708 (1.302, 2.24)

 < 0.001

1.314 (0.931, 1.854)

0.121

1.228 (0.811, 1.86)

0.331

1.174 (0.711, 1.938)

0.53

ACE-27(scores)

 0

Reference

 

Reference

 

Reference

 

Reference

 

 1

0.944 (0.767, 1.161)

0.585

0.886 (0.687, 1.143)

0.353

0.98 (0.742, 1.323)

0.889

0.658 (0.454, 0.954)

0.027

 2

1.914 (1.349, 2.716)

 < 0.001

2.112 (1.406, 3.173)

0.001

2.366 (1.5, 3.734)

 < 0.001

1.641 (0.911, 2.956)

0.095

Smoking

 No

Reference

 

Reference

 

Reference

 

Reference

 

 Yes

1.306 (1.038, 1.642)

0.023

1.302 (0.985, 1.722)

0.064

1.322 (0.95, 1.839)

0.098

1.018 (0.686, 1.511)

0.929

Chemotherapy

 No

Reference

 

Reference

 

Reference

 

Reference

 

 Yes

0.932 (0.71, 1.222)

0.608

1.043 (0.742, 1.465)

0.809

1.063 (0.715, 1.579)

0.764

1.177 (0.71, 1.953)

0.527

  1. Variables with statistical differences are in bold
  2. NPC nasopharyngeal carcinoma, WHO World Health Organization, ACE-27 Adult Comorbidity Evaluation 27, OS overall survival, DSS disease-specific survival, DMFS distant metastasis-free survival, LRRFS locoregional recurrence-free survival, HR hazard ratio, 95% CI 95% confidence interval
  3. *P values were calculated with univariate Cox proportional-hazards model
Back to article page

Radiation Oncology

ISSN: 1748-717X

Contact us